nach oben

Erschienen in:

01.11.2008 | Epidemiology

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients

verfasst von: Peter Andreas Fasching, Christian R. Loehberg, Pamela L. Strissel, Michael P. Lux, Mayada R. Bani, Michael Schrauder, Sonja Geiler, Kerstin Ringleff, Sonja Oeser, Sebastian Weihbrecht, Rüdiger Schulz-Wendtland, Arndt Hartmann, Matthias W. Beckmann, Reiner Strick

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of single nucleotide polymorphisms (SNPs) in the aromatase gene, CYP19A1, on the prognosis, and in relation to tumor and patient characteristics in a cohort of breast cancer patients. Patients and methods The cohort analyzed in this study consisted of 1,257 patients with invasive primary breast cancer. Polymorphisms rs10046, rs4646 and rs700519 were genotyped within this group. Results The variant genotypes of rs10046 and rs4646 were associated with a lower percentage of HER2-positive tumors. There was no association of rs700519 and rs4646 with disease-free survival (DFS) or overall survival (OS). The variant genotype of rs10046 was significantly associated with a better 5-year DFS (hazards ratio 0.51; 95% CI, 0.32 to 0.81; P = 0.004) adjusted for age, nodal status, tumor size grading, and hormone receptor status. This effect appeared to be determined in the subgroup of premenopausal patients. Conclusion SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS. Genotypes of aromatase polymorphisms may influence the prognosis for breast cancer patients not only by affecting the extent of estrogen exposure but also through an alteration in tumor characteristics.

Nur mit Berechtigung zugänglich

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282PubMedCrossRef

Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef

Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092PubMedCrossRef

Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139PubMedCrossRef

Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810PubMedCrossRef

Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462PubMedCrossRef

Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271PubMedCrossRef

Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRef

10.

Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757PubMedCrossRef

11.

Simpson ER, Mahendroo MS, Means GD et al (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342–355PubMedCrossRef

12.

Berstein LM, Imyanitov EN, Kovalevskij AJ et al (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207:191–196PubMedCrossRef

13.

O’Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 296:741–743CrossRef

14.

Zeitoun K, Takayama K, Michael MD et al (1999) Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol 13:239–253PubMedCrossRef

15.

Agarwal VR, Bulun SE, Leitch M et al (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81:3843–3849PubMedCrossRef

16.

Acien P, Velasco I, Gutierrez M et al (2007) Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings. Fertil Steril 88:32–38PubMedCrossRef

17.

Pathirage N, Di Nezza LA, Salmonsen LA et al (2006) Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril 86:469–472PubMedCrossRef

18.

Lu J, Li H, Cao D et al (2007) Clinical significance of aromatase protein expression in axillary node negative breast cancer. J Cancer Res Clin Oncol 133:401–409PubMedCrossRef

19.

Ribeiro FS, de Amorim LM, de Almeida Simao T et al (2006) CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women. Toxicol Lett 164:90–95PubMedCrossRef

20.

Okobia MN, Bunker CH, Zmuda JM et al (2006) Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women. J Carcinog 5:12PubMedCrossRef

21.

Kristensen VN, Andersen TI, Lindblom A et al (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8:43–48PubMedCrossRef

22.

Baxter SW, Choong DY, Eccles DM et al (2001) Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 22:347–349PubMedCrossRef

23.

Miyoshi Y, Ando A, Hasegawa S et al (2003) Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 39:2531–2537PubMedCrossRef

24.

Probst-Hensch NM, Ingles SA, Diep AT et al (1999) Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165–173PubMedCrossRef

25.

Thyagarajan B, Brott M, Mink P et al (2004) CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 207:183–189PubMedCrossRef

26.

Ralph DA, Zhao LP, Aston CE et al (2007) Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 109:1940–1948PubMedCrossRef

27.

Olson JE, Ingle JN, Ma CX et al (2007) A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 102:237–247PubMedCrossRef

28.

Kristensen VN, Harada N, Yoshimura N et al (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19:1329–1333PubMedCrossRef

29.

Haiman CA, Hankinson SE, Spiegelman D et al (2002) No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:215–216PubMed

30.

Ma CX, Adjei AA, Salavaggione OE et al (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65:11071–11082PubMedCrossRef

31.

Dunning AM, Dowsett M, Healey CS et al (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96:936–945PubMed

32.

Tworoger SS, Chubak J, Aiello EJ et al (2004) Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13:94–101PubMedCrossRef

33.

Haiman CA, Dossus L, Setiawan VW et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67:1893–1897PubMedCrossRef

34.

Guo Y, Xiong DH, Yang TL et al (2006) Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females. Hum Mol Genet 15:2401–2408PubMedCrossRef

35.

Long JR, Kataoka N, Shu XO et al (2006) Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 15:2115–2122PubMedCrossRef

36.

Blamey RW, Cataliotti L (2006) EUSOMA accreditation of breast units. Eur J Cancer 42:1331–1337PubMedCrossRef

37.

Elston EW, Ellis IO (1993) Method for grading breast cancer. J Clin Pathol 46:189–190PubMedCrossRef

38.

Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef

39.

Talbott KE, Gammon MD, Kibriya MG et al (2007) A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat. doi:10.1007/s10549-007-9794-2

40.

Zhu L, Chow LW, Loo WT et al (2004) Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 10:4639–4644PubMedCrossRef

Titel: Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients
verfasst von: Peter Andreas Fasching
Christian R. Loehberg
Pamela L. Strissel
Michael P. Lux
Mayada R. Bani
Michael Schrauder
Sonja Geiler
Kerstin Ringleff
Sonja Oeser
Sebastian Weihbrecht
Rüdiger Schulz-Wendtland
Arndt Hartmann
Matthias W. Beckmann
Reiner Strick
Publikationsdatum: 01.11.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9822-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer

Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients

Prognostic factors in long-term breast cancer survivors with brain metastases

Dietary fiber is associated with serum sex hormones and insulin-related peptides in postmenopausal breast cancer survivors

Menstrual and reproductive factors in relation to mammographic density: the Study of Women’s Health Across the Nation (SWAN)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie